The stock price of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has jumped by 5.52 compared to previous close of 10.14. Despite this, the company has seen a gain of 0.66% in its stock price over the last five trading days. zacks.com reported 2025-06-13 that Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Adaptive Biotechnologies Corp (NASDAQ: ADPT) Right Now?
Additionally, the 36-month beta value for ADPT is 1.79. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADPT is 144.91M and currently, short sellers hold a 6.65% ratio of that float. The average trading volume of ADPT on June 18, 2025 was 2.12M shares.
ADPT’s Market Performance
ADPT’s stock has seen a 0.66% increase for the week, with a 16.30% rise in the past month and a 41.53% gain in the past quarter. The volatility ratio for the week is 0.77%, and the volatility levels for the past 30 days are at 1.97% for Adaptive Biotechnologies Corp. The simple moving average for the past 20 days is 8.73% for ADPT’s stock, with a 53.63% simple moving average for the past 200 days.
Analysts’ Opinion of ADPT
Goldman, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $9. The rating they have provided for ADPT stocks is “Buy” according to the report published on March 21st, 2025.
JP Morgan gave a rating of “Overweight” to ADPT, setting the target price at $15 in the report published on July 05th of the previous year.
ADPT Trading at 19.91% from the 50-Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.56% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADPT starting from PISKEL KYLE, who sale 1,929 shares at the price of $8.89 back on May 16 ’25. After this action, PISKEL KYLE now owns 277,396 shares of Adaptive Biotechnologies Corp, valued at $17,149 using the latest closing price.
ROBINS HARLAN S, the Chief Scientific Officer of Adaptive Biotechnologies Corp, sale 68,412 shares at $7.35 during a trade that took place back on May 01 ’25, which means that ROBINS HARLAN S is holding 1,279,524 shares at $502,828 based on the most recent closing price.
Stock Fundamentals for ADPT
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.61 for the gross margin
The net margin for Adaptive Biotechnologies Corp stands at -0.75. The total capital return value is set at -0.32. Equity return is now at value -60.96, with -25.08 for asset returns.
Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -0.98. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -15.78.
Currently, EBITDA for the company is -128.76 million with net debt to EBITDA at -0.3. When we switch over and look at the enterprise to sales, we see a ratio of 8.72. The receivables turnover for the company is 4.35for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.
Conclusion
In conclusion, Adaptive Biotechnologies Corp (ADPT) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
